FDA Approves Selpercatinib for Pediatric Patients With RET-Altered Metastatic Thyroid...

cafead

Administrator
Staff member
  • cafead   May 29, 2024 at 10:02: PM
via The FDA granted accelerated approval to selpercatinib (Retevmo) for the treatment of pediatric patients aged 2 years and older with RET-altered metastatic thyroid cancer or solid tumors.

article source
 

<